Publication details

Aktuální možnosti biologické léčby u axiálních spondyloartritid

Authors

PROCHÁZKOVÁ Leona

Year of publication 2018
Type Article in Periodical
Magazine / Source Farmakterapeutikcká revue
MU Faculty or unit

Faculty of Medicine

Citation
Keywords axial spondyloarthritis biological disease modifying antirheumatic drugs IL-17 inhibition, TNF-a inhibitors
Description Therapy of axial spondyloarthritis is a complex task. The major target in the treatment is suppression of inflammation, reducing clinical symptoms of disease and preventing structural progression. An integral part of the therapy is the extra-articular manifestations occurring in a large number of patients. Regular exercises in combination with non-steroidal anti-inflammatory drugs are the basis for therapy, and in case of insufficient effect, biological therapy is indicated. For more than a decade, the only option of biological treatment was TNF-a blockade. The portfolio of biologic drugs for axial spondyloarthritis has recently expanded the fully human monoclonal antibody against IL-17A, secukinumab. All 5 TNF-a inhibitors and secukinumab can be used to treat the radiographic form of the disease, there are some differences in efficacy of TNF-a inhibitors in treatment of extra-skeletal manifestations. The expanding spectrum of biological therapy is thus a therapeutic option that makes remission of the disease a real goal.

You are running an old browser version. We recommend updating your browser to its latest version.

More info